Nothing Special   »   [go: up one dir, main page]

AR110682A1 - T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM - Google Patents

T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM

Info

Publication number
AR110682A1
AR110682A1 ARP170103446A ARP170103446A AR110682A1 AR 110682 A1 AR110682 A1 AR 110682A1 AR P170103446 A ARP170103446 A AR P170103446A AR P170103446 A ARP170103446 A AR P170103446A AR 110682 A1 AR110682 A1 AR 110682A1
Authority
AR
Argentina
Prior art keywords
antigen
tcr
nucleic acids
immune therapy
taa
Prior art date
Application number
ARP170103446A
Other languages
Spanish (es)
Inventor
Bunk Sebastian Dr
Alten Leonie Dr
Maurer Dominik Dr
Wagner Claudia Dr
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR110682A1 publication Critical patent/AR110682A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Construcciones que reconocen antígenos dirigidas contra antígenos asociados a tumor (MAGEA1); moléculas basadas en el receptor de células T (TCR) que son selectivas y específicas para el antígeno expresado en tumores. El TCR, y los fragmentos de unión a TAA derivados del mismo, son útiles para el diagnóstico, tratamiento y prevención de enfermedades cancerosas que expresan el TAA. Además se proveen ácidos nucleicos que codifican para las construcciones que reconocen antígenos, vectores que comprenden estos ácidos nucleicos, células recombinantes que expresan las construcciones de reconocimiento de antígenos y composiciones farmacéuticas.Constructions that recognize antigens directed against tumor associated antigens (MAGEA1); T-cell receptor-based molecules (TCR) that are selective and specific for tumor-expressed antigen. TCR, and TAA binding fragments derived therefrom, are useful for the diagnosis, treatment and prevention of cancerous diseases that express TAA. In addition, nucleic acids encoding the antigen-recognizing constructs, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognition constructs and pharmaceutical compositions are provided.

ARP170103446A 2016-12-08 2017-12-07 T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM AR110682A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662431588P 2016-12-08 2016-12-08

Publications (1)

Publication Number Publication Date
AR110682A1 true AR110682A1 (en) 2019-04-24

Family

ID=66326301

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103446A AR110682A1 (en) 2016-12-08 2017-12-07 T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM

Country Status (2)

Country Link
AR (1) AR110682A1 (en)
EA (1) EA201991151A1 (en)

Also Published As

Publication number Publication date
EA201991151A1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
CO2019006914A2 (en) New t-cell receptors and immune therapy that uses them
CL2020001181A1 (en) New genetically modified T-cell receptors and immune therapies using them.
CR20190278A (en) Novel t cell receptors and immune therapy using the same
MX2023003463A (en) T cell receptors and immune therapy using the same against prame positive cancers.
CR20190276A (en) Novel t cell receptors and immune therapy using the same
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
MX2019001769A (en) T cell receptors and immune therapy using the same.
PH12019500312A1 (en) T cell receptors and immune therapy using the same
MX2020001996A (en) Anti-cd137 molecules and use thereof.
ECSP17027870A (en) COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY
EA201891459A1 (en) NEW GENERATION OF ANTIGENSPECIFIC TCR
BR112022004407A2 (en) Bispecific immunotherapy of antibody car cells
AR110682A1 (en) T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM
EA202090712A1 (en) NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE
AR113834A1 (en) GENETICALLY MODIFIED T-CELL RECEPTORS AND IMMUNE THERAPIES THAT USE THEM
CO2019006926A2 (en) New T-cell receptors and immune therapy that uses them
CY1124826T1 (en) T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM
EA201992002A1 (en) T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION
AR110504A1 (en) T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM
AR109345A1 (en) T-LYMPHOCYTE AND IMMUNOTHERAPY RECEPTORS BASED ON THE USE OF THE SAME
EA201990488A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
UY36344A (en) COMPOSITIONS AND METHODS USED TO INCREASE THE IMMUNE RESPONSE AND IN CANCER THERAPY